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a b s t r a c t
We investigated the origin and the effect of insertion D67D-THGERDLGPA within HIV-1 RT from a
patient failing antiviral therapy. The insertion developed within the context of pre-existing NRTI and
NNRTI mutations (M41L, L210W, T215Y and N348I). Concurrently, the NRTI mutations T69I and V118I
and the NNRTI mutations K103N and Y181C were detected for the ﬁrst time. High-level drug resistance
(fold-changesZ50) and a good replication capacity (87% of wild-type) were observed, signiﬁcantly
higher than for the previous virus without insertion. The insertion was very similar to a region within
human chromosome 17 (31/34 nucleotide identity), and had already been detected independently in a
Japanese HIV-1 isolate. These results suggest that a particular sequence within human chromosome 17 is
prone to horizontal gene transfer into the HIV-1 RT ﬁnger subdomain. This insertion confers selective
advantage to HIV-1 by its contribution to multi-drug resistance and restoration of impaired replication
capacity.
& 2014 Elsevier Inc. All rights reserved.
Introduction
Nucleoside reverse transcriptase (RT) inhibitors (NRTIs) still
remain the cornerstone of current antiretroviral therapy (ART)
against human immunodeﬁciency virus type 1 (HIV-1) (DHHS,
2014). Initial treatment regimens usually consist of 2 NRTIs in
combination with either 1 non-NRTI (NNRTI), 1 boosted protease
inhibitor (PI/r) or 1 integrase inhibitor (INI). Even in second line
regimens, NRTIs form the backbone of the combination ART
(cART), provided NRTI resistance is not too extensive. Moreover,
NRTIs are important players in the prevention of mother to child
transmission and their role in treatment as prevention (TasP) and
pre-exposure prophylaxis (PrEP) is being extensively investigated
(Gupta et al., 2013). During the last few years the gamut of
antiviral drugs available for the treatment of HIV-1 has increased
and diversiﬁed substantially. This has contributed to the successful
decrease in morbidity and mortality in HIV-1 patients, even in
patients who had failed multiple antiretroviral regimens (Gulick
et al., 2008; Lazzarin et al., 2003; Madruga et al., 2007; Steigbigel
et al., 2008).
Due to the high replication rate, the lack of proofreading
activity and the template switching of RT, drug-resistant genetic
variants can develop which may limit the success of cART. In this
respect, HIV-1 can develop resistance against all NRTIs, either
through mutations that selectively discriminate between the
inhibitor and the dNTP or through mutations that enhance the
excision of the incorporated inhibitor (Menendez-Arias, 2010).
For example, the thymidine analog mutations (TAMs) are a
combination of M41L, D67N, K70R, L210W, T215Y/F and K219Q/E
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in RT, mainly selected by thymidine analogs zidovudine (AZT) and
stavudine (d4T), but conferring resistance to all NRTIs when multiple
mutations are present (Demeter et al., 1995; Kellam et al., 1992; Larder
and Kemp, 1989). Another form of multi-NRTI resistance is referred to
as the Q151M pathway (A62V, V75I, F77L, F116Y and Q151M) (Shafer
et al., 1994). High-level resistance to antiviral drugs generally arises by
stepwise accumulation of mutations, rather than insertions or dele-
tions (Johnson et al., 2013), but insertions and deletions contributing
signiﬁcantly to drug resistance have been described. These seem
especially important in affecting the RT ﬁnger subdomain and have
occasionally been observed in HIV-1 patients not responding to cART
with a prevalence ranging from 0.6% to 4.1% (Andreoletti et al., 2002;
Balotta et al., 2000; Briones et al., 2001; Bulgheroni et al., 2004; de
Jong et al., 1999; Kaliki et al., 2000; Larder et al., 1999; Lukashov et al.,
2001; Mas et al., 2000; Masquelier et al., 2001; Rakik et al., 1999; Ross
et al., 1999, 2000; Sato et al., 2001; Schneider et al., 2004; Sugiura et
al., 1999; Tamalet et al., 1998, 2000; van der Hoek et al., 2005; Van
Vaerenbergh et al., 2000; Winters et al., 1998).
The aim of this study was to investigate the origin of an
uncommon 10-amino acid insertion within the ﬁnger subdomain
of HIV-1 RT from a patient failing cART. We want to address the
impact of the insertion by characterizing the genotypic and
phenotypic viral proﬁle.
Results
Therapy history and in vivo evolution of genotypic drug resistance
The Belgian HIV-1 patient was diagnosed in 1993 with a subtype A
strain and was presumably heterosexually infected in Sub-Saharan
Africa. He received AZT monotherapy for a short period in 1994
(Fig. 1). The surveillance began in 1996, but a baseline plasma sample
was absent. However, two PBMC samples isolated while the patient
was receiving AZT and zalcitabine (ddC) were available for retro-
spective drug resistance analysis. Genotypic drug resistance testing
was performed on plasma samples as part of routine clinical care
between 2000 and 2007. Sequence analysis revealed the presence of
M41M/L, L210L/W and T215T/N/Y/S (sample 1), followed by the full
replacement of M41L and T215Y, together with the disappearance of
L210W (sample 2). Both samples contained the mutations K20K/R and
L89M in protease. In 1997, AZT and ddC were replaced by 3TC and d4T.
A few months later, saquinavir mesylate (SQV) was added to the
regimen, subsequently replaced by indinavir (IDV) after a few more
months. At the beginning of 1999, boosted saquinavir (SQV/r) was
initiated instead of IDV and ABC replaced 3TC. During treatment with
this regimen, the NRTI mutation L210Wand the NRTI/NNRTI mutation
N348I appeared together with the PI mutation I84V and the full
replacement of K20R (sample 3). Under the selective pressure of IDV/r,
ABC and NVP, sample 4 was isolated in which the insertion D67D-
THGERDLGPA and the mutations T69I, K103N, V118I and Y181C were
also observed within RT. However, the NNRTI mutation N348I and the
PI mutation I84V had disappeared. Subsequently, the NRTI mutations
L74L/I and T215C, the NNRTI mutations K101K/Q and G190G/A, and
the PI mutations K20R/I, I54V, V82A and L89M/I appeared under
selective pressure of ABC, EFV and boosted lopinavir (LPV/r) (sample
5). Moreover, V118I was absent at this time. On the patient's ﬁnal
regimen (ddI, ABC, fosamprenavir (FPV) and LPV/r), K20R in PR and
M41L and L74I in RT were not observed anymore, whereas A98A/G,
K103N/H, V118V/I and G190A were also detected in RT and L10F and
T74A in PR (sample 6).
in vivo evolution of insertion
PCR fragments containing the RT gene of the last clinical sample
without insertion (sample 3) and the ﬁrst with insertion (sample 4)
were cloned. Nine clones from each sample were sequenced. None of
the clones from sample 3 displayed the insertion, in contrast to
the clones from sample 4 that all contained the insertion (Fig. 2).
The insertion at RT position 67 remained present during the entire
investigated time period of 6 years, although some residues did
evolve. In sample 4, one clone displayed arginine (Arg) at the second
amino acid position within the insertion. For the last 2 samples, only
population-based sequences were obtained. Sample 5 displayed a
mixture of histidine (His) and tyrosine (Tyr) at the second amino acid
position in the insertion. Mixtures of threonine (Thr) and proline
(Pro) at the ﬁrst and of leucine (Leu) and glutamine (Gln) at the
seventh amino acid position of the insertion were present in
sample 6.
Drug susceptibility and replication capacity
Clonal fragments representative of samples 3 and 4 were used
to generate RT-recombinant viruses (Table 1). Sequencing of the
recombinant viruses conﬁrmed a genotypic proﬁle within RT
identical to the original clone. Drug susceptibility testing of sample
3 revealed resistance towards all tested NRTIs and NNRTIs,
although not all values were signiﬁcantly different from wild-
type due to inter-assay variability (Table 1). The drug resistance
levels varied for the NRTI drug class between 3-fold towards ddI
and 267-fold towards AZT, and for the NNRTI drug class between
12-fold towards EFV and 83-fold towards NVP. From sample 4 it
seems that drug resistance levels to all drugs increased substan-
tially, with drug resistance levels ranging from 50-fold towards
3TC to more than 2130-fold towards AZT. Resistance against NVP
increased to more than 168-fold and against EFV to 71-fold. Both
viruses remained susceptible to PFA. The replication capacity of
sample 3 was strongly impaired, reaching 34% of the HIV-1 wild-
type's capacity (k-value 0.74 vs. 2.15). The capacity to replicate was
partly restored in sample 4 which displayed 87% compared to HIV-
1 wild-type (k-value 1.87 vs. 2.15).
Homologous nucleotide sequences to the observed insertion
As the insertion did not result from any duplication of nearby
nucleotides, several PCR fragments covering the entire HIV-1
genome (sample 4) were sequenced to determine the origin of
the 10-amino acid insertion. The BLAST program was used to
compare its encoding nucleotide sequence plus 3 extra nucleotides
adjacent to each side with the full HIV-1 genome. The highest
scores were from two hits that consisted of 8/8 identities with an
E-value of 2.4. As this analysis did not reveal an autologous origin
of the entire insertion, all sequences available at the NCBI database
were checked. This search revealed sequence homology with a
region within human chromosome 17 (31/34 nucleotide identity,
E-value of 0.002) and with the amino terminal part of RT from an
HIV-1 isolate (99JP-NH3-II, 26/27 nucleotide identity, E-value of
0.006) (Fig. 2). All other hits, not related to the previous two,
displayed E-values above 6.7.
Interestingly, the former hit was speciﬁcally matched with the
reverse complement of a particular gene within human chromo-
some 17 (GenBank AC135178, NT positions 136,586–136,553) that
encodes component 1 of the CTS telomere maintenance complex
(GenBank NG032148, cytogenetic location 17p13.1, molecular loca-
tion NT positions 8,128,138–8,151,412 of chromosome 17 (Genbank
NC_000017.10)). We then sequenced a 339-bp PBMC DNA fragment
to conﬁrm that the patient-derived sequence was identical to
AC135178 in GenBank. The match overlapped with an exon–intron
boundary of the respective gene (NT positions 5099–5066).
The latter hit relates to a nucleotide sequence that encodes
an 11-amino acid insertion at RT position 67 in an HIV-1
CRF01_AE isolate from a Japanese patient (GenBank AB053002)
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(Sato et al., 2001). The insertion differed from the one observed in
our study at 5 nucleotide positions and contained an extra codon
(Fig. 2).
Genetic linkage between HIV-1 patients displaying a similar insertion
To ascertain whether the HIV-1 strains of the two patients were
linked, we determined the phylogenetic relationships of the
sequences. Our analysis included HIV-1 subtype A and CRF01_AE
sequences from the local HIV-1 epidemics and the sequences most
similar to the investigated strains according to BLAST. The strains
from the Belgian and Japanese patient did not cluster together in
the phylogenetic tree (Fig. 3). They belonged to the subtype A and
CRF01_AE clusters, respectively, supported by bootstrap values of
94%. We can therefore exclude the possibility that this insertion
occurred only once and was passed on between the two patients,
and conclude that the insertion resulted from convergent
evolution.
Mapping of the wild-type residues on HIV-1 reverse transcriptase
To provide structural evidence, the mutated residues and the
insertion position were mapped to the crystalized RT in the
presence of AZT and NVP (Fig. 4). This model conﬁrmed the drug
resistance conferred by the mutations and particularly by the
insertion. The insertion, colored in red, was found to be near the
catalytic area of RT where the dsDNA is synthesized, thereby
impeding the binding of AZT. Furthermore, selected NNRTI
mutations at positions 103 and 181 have an Euclidian distance
of 4.95 Å and 4.66 Å to NVP, respectively, indicating strong
contact at molecular level. Similarly, the selected NRTI mutations
at positions 67–69 and 215 are close to AZT (Euclidean distances
o8 Å). The positions 41, 118, 210 and 348 are located further
away from those drugs, so a direct interaction with AZT and NVP
is less likely.
Discussion
In an HIV-1-infected patient failing ART, a 10-amino acid
insertion (THGERDLGPA) was observed at position 67 in the
β3–β4 loop of the HIV-1 RT ﬁnger subdomain. The positions in
RT most prone to insertions are located between RT codons 68 and
70. Insertions of two amino acids have mainly been reported at RT
position 69 in clinical isolates from HIV-1 patients failing ART.
These insertions typically confer NRTI resistance in association
with TAMs (Larder et al., 1999; Mas et al., 2000; Meyer et al., 2003;
White et al., 2004; Winters et al., 1998). As the ﬁnger subdomain
traps the dNTP and precisely aligns the α-phosphate of the dNTP
and the 30-OH of the primer inside the polymerase active site, we
wanted to investigate the origin and phenotypic effect of this large
insertion near the catalytic site (Fig. 4).
Thymidine analogs seem to be important players in the selec-
tion process of 69-insertions as all but one study reported AZT
therapy prior to their selection. In that study, two patients were
exposed only to d4T (Ross et al., 1999). In patients developing 69-
insertions, the most common course of treatment is AZT mono-
therapy, followed by a combination of AZT with either ddI or ddC.
In the study patient, the insertion was only detected in samples
after the combination of ABCþNVPþ IDV/r was prescribed (Fig. 1).
However, the patient had been pre-exposed to AZT monotherapy
and several regimens containing either AZTþddC, d4Tþ3TC and
d4TþABC.
The key role of thymidine analogs is also manifested by the
occurrence of 69-insertions mainly within the context of TAMs,
and more speciﬁcally within the TAM1 pathway (M41L, L210W
and T215Y) (Larder et al., 1999; Matamoros et al., 2004; Scherrer et
al., 2012; Tamalet et al., 2000). Although 69-insertions are typically
preceded by a mutation from threonine to serine at position 69
(T69S) (Larder et al., 1999), our study described an insertion
positioned between RT codons 67 and 68, which appears to have
developed together with the mutation T69I. In the study patient,
the TAM1 mutations were already detected in a sample frommany
years before the sample with insertion, whereas the minor NRTI
Fig. 1. History of viral load, therapy and drug resistance mutations in PR and RT. Only positions that are implemented within genotypic drug resistance interpretation
systems Rega v8.0.2 or HIVdb v6.2 are enlisted. Positions associated with NNRTI resistance are underlined. n/a, not available. Positions according to NL4.3 (AF324493). 3TC,
lamivudine; ABC, abacavir; AZT, zidovudine; d4T, stavudine; ddC, zalcitabine; ddI, didanosine; EFV, efavirenz; IDV, indinavir; IDV/r, ritonavir-boosted indinavir; FPV,
fosamprenavir; LPV/r, ritonavir-boosted lopinavir; NVP, nevirapine; SQV, saquinavir; SQV/r, ritonavir-boosted saquinavir.
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mutation V118I and the major NNRTI mutations K103N and Y181C
were detected for the ﬁrst time in the same sample as the
insertion (Fig. 1).
It has been reported that the majority of 69-insertions do not
confer resistance by themselves (Harrigan et al., 2007; Larder et
al., 1999). In contrast to the most common insertion 69S-SS, the
insertions 69S-SA and 69S-SG were nevertheless associated with
some reduced NRTI susceptibility in the absence of other geno-
typic changes (Meyer et al., 2003). It is proposed that insertions
and deletions within the β3–β4 HIV-1 RT loop increase the NRTI
excision due to the destabilization of the dead-end complex
instead of an increased ATP-binding (Boyer et al., 2001; Tu et al.,
2010). In our study, the sample without insertion already dis-
played some NRTI resistance due to the TAM1 mutations and the
level of resistance was strongly enhanced after the addition of the
insertion (Table 1). Surprisingly, NNRTI resistance was observed in
the absence of major NNRTI mutations and the level of resistance
was further elevated after the selection of K103N and Y181C. The
unexpected phenotypic NNRTI resistance prior to in vivo NNRTI
exposure and without major NNRTI mutations could be explained
by the presence of N348I. N348I is a mutation within the HIV-1
RT connection subdomain that previously had been reported in
therapy-naïve and treated patients (0.8% and 12.1% respectively)
(Yap et al., 2007). In patients treated with solely NRTI or with
regimens containing NRTI and NNRTI, the mutation is usually
observed in combination with TAMs with or without K103N/
Y181C. These particular mutation combinations confer subse-
quently dual-class resistance, irrespective of the presence of major
NNRTI mutations (Yap et al., 2007).
Regarding the impact of 69-insertions on the viral replication
capacity, contradictory results have been reported. In the absence
of drugs, insertions of different lengths had a negative impact on
the replication capacities, although some studies reported replica-
tion capacities and polymerase activities comparable to wild-type
(Huigen et al., 2007; Kew et al., 1998; Prado et al., 2004; Quinones-
Mateu et al., 2002). In our sample, the insertion was able to partly
restore the diminished replication capacity of the mutant virus
displaying TAMs. Additionally, in vivo data suggested that the large
insertion conferred selective advantage and was well tolerated as
the insertion was retained for more than 6 years during a period in
which cART was frequently changed.
Most of the reported HIV-1 insertions are simple duplications
of neighboring sequences but a long-distance ectopic duplication
of 15 nucleotides from the env into the pol gene has also been
observed in HIV-1 (Lobato et al., 2002). However, the insertion
present in the study patient was not a duplication of neighboring
nor ectopic sequences. A BLAST search of all the sequences in
GenBank revealed homology between our insertion and the
Fig. 2. Analysis of HIV-1 RT subdomain sequences. The upper and lower panels display respectively the nucleotide and amino acid alignment of the region immediately up-
and downstream of the insertion. Positions are in accordance to HIV-1 NL4.3 (AF324493). The upper row is the reverse complement of the sequence fragment from
chromosome 17 (open reading frame 68, chr17 ORF68) (AC135178) that matches to the insertion. 99JP-NH3-II is a clinical HIV-1 isolate from a Japanese child displaying a
similar insertion (AB053002). Information on the 9 clones obtained for sample 4 is displayed in lower-case. Residues identical to the reference, whether NL4.3 or chr17
ORF68, are replaced by dots.
Table 1
Phenotypic characteristics of recombinant viruses.
Sample Drug susceptibilitya Replication capacity b
Drug AZT d4T ddI 3TC ABC TDF NVP EFV PFA
3 mFC7SD 267776 6.3670.99 2.6170.31 3.871.3 5.472.6 13.073.7 83734 12.472.1 0.3370.12 k 0.74
P-value 0.026 0.011 0.012 0.068 0.10 0.031 0.18 0.082 0.002 R² 0.94
4 mFC7SD 42130 484 52.878.8 49.678.7 4263 54.474.2 4168 71.474.7 0.50 k 1.87
P-value – – 0.076 0.081 – 0.035 – 0.0015 0.21 R² 0.99
3 vs. 4 P-value – – 0.0017 0.0023 – 0.0013 – 0.00050 0.28 P-value 0.012
a For each independent experiment, the mean IC50 value of the recombinant virus was compared to the mean IC50 value of the wild-type virus from triplicates,
generating the fold change (FC). The mean fold change (mFC) was calculated as the mean FC of independent experiments. SD, standard deviation of the mFC. P-value
obtained with two-sided student's t test. 3TC, lamivudine; ABC, abacavir; AZT, zidovudine; d4T, stavudine; ddI, didanosine; EFV, efavirenz; NVP, nevirapine; PFA, foscarnet;
TDF, tenofovir.
b Slope k of regression curve log 10 (fold replication capacity)¼ekt and time t as intervals of 24 h after 72 h post-inoculation. For parental virus NL4.3 k¼2.15 and
R²¼0.93.
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human chromosome 17 orf 68, encoding the CTS telomere main-
tenance complex component 1 (CTC1), as well as with a pol
insertion observed in a Japanese HIV-1 patient (Sato et al., 1999).
Epidemiological and clinical information did not indicate a direct
linkage between the study patient and the Japanese patient. Our
patient was an adult Caucasian male who was HIV-1 diagnosed in
Belgium in 1993 and was probably heterosexually infected in Sub-
Saharan Africa, whereas the Japanese patient was born from a
seropositive mother in Japan in 1991 (Sato et al., 1999). The mother
was most likely infected by her husband who had a history of sexual
contacts with female prostitutes in Thailand in 1989–1990. Further-
more, only the HIV-1 strain from her child developed the insertion
after exposure to AZTþddI, followed by AZTþ3TCþNFV/IDV in 1999
(Sato et al., 2001). The phylogenetic analysis conﬁrmed that the two
patients could not have infected each other.
Therefore, the detection of an identical human genome
sequence from chromosome 17 at an identical location in the
HIV-RT of two epidemiological unlinked patients indicates a
separate mutation event. It suggests that both sites in the human
and viral genome are prone to host sequence transduction and
that it provides an evasion mechanism to the virus under
therapeutic pressure. The minus-strand exchange model is cur-
rently the favored model for retroviral genetic recombination
(Onafuwa-Nuga and Telesnitsky, 2009). In this model, RNase
H-mediated template degradation exposes the nascent minus
strand DNA and enables its subsequent hybridization with
complementary regions on the other co-packaged viral RNA
(acceptor template). It is suggested that host sequence transduc-
tion can occur when the provirus is integrated upstream of the
host derived insert-coding region (Onafuwa-Nuga and Tele-
snitsky, 2009). Read-through of the polyadenylation signal could
then lead to the generation of a chimeric retroviral–human RNA
that is encapsulated in budding virions. As host sequence
transduction mostly reveals the absence of identity between
donor and acceptor template behind the junctions, recombina-
tion is driven by only short stretches of sequence identity,
enabling the transfer of the primer terminus to the acceptor
template. Indeed, codon AGC at HIV-1 RT position 68 in our study
patient might have facilitated the recombination event as it
matches to the NT sequences adjacent to the human genome
insertion (Fig. 2). Of interest, AGC is rarely observed in most
strains from all subtypes (range from 2.5% to 7.02%), except in
Fig. 3. Phylogenetic analysis of the Belgian and Japanese RT sequences (colored in red and blue, respectively), together with the most similar HIV-1 sequences and with HIV-
1 subtype A and CRF01_AE sequences from the local epidemics. Manual phylogenetic analysis was performed using the neighbor joining method (HKY-parameter, bootstrap
1000). The tree was midpoint rooted to allow easier visualization.
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subtype A (90.37%), CRF01_AE (79.57%), subtype J (35.14%) and
subtype K (25%). As the insertions in both patients differed from
the modeled founder sequence at a few nucleotide positions,
subsequent rearrangements and point mutations would have
contributed to the observed genetic changes.
In conclusion, the in vivo retention of the 10-amino acid
insertion for more than 6 years suggests that the insertion is
well-tolerated. Together with the high-levels of in vitro NRTI
resistance and replication capacity, the insertion is likely to deliver
a selective advantage in the presence of NRTI-containing ART.
As the horizontal gene transfer has been observed to occur
independently in two unrelated patients carrying different sub-
types of HIV-1, it can be considered as a typical example of
convergent evolution.
Nucleotide sequence accession numbers
Sequences have been submitted to GenBank under accession
numbers KJ438641–KJ438646.
Materials and methods
Patient samples
Plasma and PBMC samples were obtained from a patient
attending the AIDS Reference Center at the University of Liège.
Plasma viral load was determined using the Amplicor HIV-1
Monitor Test (Roche Diagnostics, Vilvoorde, Belgium).
Cells, compounds and plasmids
Human embryo kidney cells (293T) (ATCC, LGC Standard,
Teddington, UK), U87.CD4.CCR5.CXCR4 cells and MT-4 cells were
cultivated as previously described (Covens et al., 2009; Miyoshi
et al., 1981; Princen et al., 2004).
Zidovudine (AZT), abacavir (ABC), stavudine (d4T), didanosine
(ddI), lamivudine (3TC), nevirapine (NVP) and efavirenz (EFV)
were obtained through the AIDS Research and Reference Reagent
Program (Division of AIDS, NIAID, NIH). Tenofovir (TDF) was kindly
provided by Gilead Sciences (Foster City, CA). Foscarnet (PFA) was
purchased from Sigma-Aldrich (Diegem, Belgium).
The molecular clone used to generate recombinant viruses was
pNL4.3-ΔRT-EGFP (Covens et al., 2009). It displays a deletion from
RT codons 1 to 560 and contains the gene encoding an enhanced
green ﬂuorescent protein (EGFP) between env and nef without
affecting the expression of any HIV gene.
Extraction, ampliﬁcation and cloning of viral genome fragments
One milliliter of plasma from clinical samples was ultra-
centrifuged at 37,100g for 1 h and subsequently RNA was extracted
using the extraction procedure from the Viroseq HIV-1 Genotyping
System (Abbott Molecular, Louvain-La-Neuve, Belgium). DNA was
extracted from PBMC samples using the QIAamp DNA minikit
(QIAGEN, Venlo, The Netherlands). For recombinant viruses, 20 ml
of virus supernatant was lysed with 560 ml AVL buffer (QIAGEN)
while incubated for 10 min at room temperature. Subsequently,
viral RNA was precipitated with isopropanol, washed with 70%
ethanol and resuspended in 50 ml of RNase-free water (Sigma-
Aldrich).
Several fragments covering nearly the entire HIV-1 genome
were ampliﬁed using the SuperScript™ III One-Step RT-PCR
System with Platinums Taq High Fidelity (Life Technologies, Gent,
Belgium) in the outer PCRs and Expand High Fidelity PCR System
(Roche Diagnostics) in the inner PCRs (Covens et al., 2009; Snoeck
et al., 2005; Van Laethem et al., 2005, 2006, 2008). The RT
ampliﬁcation products were directly inserted into a plasmid using
the TOPO XL PCR Cloning Kit (Life Technologies). Single trans-
formed Escherichia coli cells were incubated overnight in a shaking
incubator at 37 1C using 5 ml LB medium.
Fig. 4. Mapping of the mutated residues on the HIV-1 RT structure (PDBID: 1RTD) using Yasara (Krieger et al., 2002). The HIV-1 RT p66 unit, p51 unit and the DNA/RNA
heteroduplex are colored pink, light blue and yellow, respectively. The structures of AZT and NVP drugs are represented. Mutated residues observed in sample 3, sample 4 or
in both samples are colored in blue, red and orange respectively.
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Extraction and ampliﬁcation of human genome fragments
Human genomic DNA was extracted from PBMC samples using
the QIAamp DNA Mini Kit (QIAGEN) and a 339-bp fragment was
ampliﬁed using primers KVL126 (50-TAG GAA GCG AGG GGG TGA
GCA GCG AG-30) and KVL127 (50-AGA ACC AGT AAG AGG TAG GAG
CGG ACC GAC-30), Expand High Fidelity PCR System (Roche
Diagnostics) and 2 mM MgCl2. The ampliﬁcation started with an
initial denaturation at 94 1C for 2 min, followed by 40 cycles of
denaturation at 94 1C for 15 s, annealing at 58 1C for 30 s and
elongation at 72 1C for 1 min, with a ﬁnal elongation at 72 1C for
5 min.
Sequencing
PCR products and plasmids were puriﬁed with Microspin S-400
(GE Healthcare, Diegem, Belgium) and QIAprep Miniprep Kit
(QIAGEN), respectively. Sequencing was performed using the ABI
PRISM BigDye Terminator v3.1 Ready Reaction Cycle Sequencing
Kit (Life Technologies) and reactions were run on an ABI3130xl
Genetic Analyzer (Life Technologies). The sequences were ana-
lyzed using Sequence Analysis version 3.7 and SeqScape version
2.0 (Life Technologies) (Covens et al., 2009; Snoeck et al., 2005;
Van Laethem et al., 2005, 2006, 2008). Subtype was automatically
assigned using Rega Subtyping Tool version 2.0 (de Oliveira et al.,
2005).
Phylogenetic and transmission cluster analysis
Highly similar sequences were searched using default settings
in nucleotide BLAST (BLASTN) via NCBI (available at http://blast.
ncbi.nlm.nih.gov) (Altschul et al., 1997) and the nucleotide collec-
tion database (nr/nt, all GenBankþEMBLþDDBJþPDB sequences).
Expect values (E) are those assigned by BLASTN using default gap
and mismatch penalties. The E-value is a parameter that describes
the number of hits that can be expected by chance when searching
a database of a particular size.
Control PR–RT nucleotide sequences for subtype A and
CRF01_AE were downloaded from the Los Alamos HIV Database
(http://www.hiv.lanl.gov/), from where one sequence per patient
was obtained. Sequences were aligned using ClustalW. Insertion
and positions associated with drug resistance were removed from
the alignment (Bennett et al., 2009). Phylogenetic analysis was
performed using the neighbor joining method in SeaView version
4 (HKY-parameter, bootstrap 1000) (Gouy et al., 2010).
Drug susceptibility and replication capacity
RT-recombinant viruses containing the EGPF gene were gener-
ated as previously described (Covens et al., 2009). In brief, 2 mg of
puriﬁed RT-PCR product (QIAquick PCR Puriﬁcation Kit, QIAGEN)
and 10 mg of puriﬁed XbaI-digested pNL4.3-ΔRT-EGFP (PuriLink
HiPure Plasmid Filter Puriﬁcation Kit, Life Technologies) were co-
transfected in 293T cells using the standard calcium-phosphate
method. Subsequently, the supernatant was transferred to freshly
plated U87.CD4.CCR5.CXCR4 cells and cell cultures were moni-
tored for EGFP-expression using ﬂuorescence microscopy. Virus
supernatant was harvested using low speed centrifugation and
stored at 80 1C for later use. The RT sequence of the recombinant
viruses was conﬁrmed as previously described (Covens et al.,
2009). In 3 triplicate experiments, drug susceptibilities towards
AZT, ABC, d4T, TDF, ddI, 3TC, NVP, EFV and PFA were determined in
U87.CD4.CCR5.CXCR4 cells 44 h after infection by measuring EGFP-
expression by ﬂow cytometry. Two-sided one-sample t-tests
(Po0.05) were performed using GraphPad Prism version 5.01 for
Windows (GraphPad Software, San Diego, California, USA).
For the analysis of replication capacity, one million exponen-
tially growing MT-4 cells were infected with recombinant viruses
(pre-diluted to achieve 0.1% of EGFP-positive cells after 72 h) in a
total volume of 500 μl. The testing was done three times in
triplicate for each virus in 24-well plates. After 4 h, the remaining
viruses were washed away with PBS and cells were cultured in
2 ml of RPMI to propagate MT-4 cells at 37 1C. Seventy-two hours
after infection, the amount of cells was normalized to
750,000 cells/ml and excess cells were ﬁxed with 2% paraformal-
dehyde. This procedure was repeated every 24 h for 72 h (i.e. 96,
120 and 144 h after infection). The percentage of EGFP-expressing
cells was determined using ﬂow cytometry. The amount of
infected cells was normalized to the percentage of infected cells
at 72 h (day 0). The curves were ﬁtted exponentially and the
resulting k-values (y¼ekt) were used as a measure of replication
capacity (Auwerx et al., 2008; Brockman et al., 2006). Two-sided
two-sample t-tests (Po0.05) were performed using GraphPad
Prism version 5.01 for Windows (GraphPad Software).
Mapping of the insertion on HIV-1 RT
The graphic representations of the HIV-1 RT structure in complex
with AZT and NVP were generated using the Yasara program (version
13.2.21) (Krieger et al., 2002). The HIV-1 RT structure (PDBID: 1RTD)
was superposed on the structures containing AZT (PDBID: 3V4I) and
NVP (PDBID: 4B3Q). Yasara was used to map mutations and the
inserted loop using the BuildLoop command. The OptimizeLoop
command was run to improve the conformation of the loop. Pymol
v1.5 (http://www.pymol.org/) was used to evaluate the structural
contacts between the inhibitors (AZT or NVP) and RT mutations
calculating the minimum Euclidean distances between atoms of
inhibitors and non-hydrogen atoms of residues (Duarte et al.,
2010). Contacts were considered direct when the Euclidean distance
between inhibitor and residue was less than 8 Å in the RT structure
(Morcos et al., 2011).
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